出自:ASN 2020-Oral Abstract Session,High-Impact Clinical Trials-FR-OR58. Effects of Dapagliflozin on Kidney Function, Cardiovascular Events, and All Cause Mortality According to Cause of Kidney Disease in the DAPA-CKD Tri...
7.Heerspink HJL,Stefansson BV,Chertow GM,et al.Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease(DAPA-CKD)randomized controlled trial.Nephrology,dialysis,transplantation:official ...
Effects of Dapagliflozin in Patients without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial 达格列净对不合并糖尿病且存在微量白蛋白尿患者的影响:DAPA-CKD试验的探索性分析 01研究背景 DAPA-CKD研究表明,SGLT2i达格列净可减缓合并或不合并2型糖尿病的CKD患者的进行性肾功能减退。
Effects of Dapagliflozin in Patients without Diabetes and Microalbuminuria: An Exploratory Analysis From the DAPA-CKD Trial 达格列净对不合并糖尿病且存在微量白蛋白尿患者的影响:DAPA-CKD试验的探索性分析 01研究背景 DAPA-CKD研究表明,SGLT2i达格列净可减缓合并或不合并2型糖尿病的CKD患者的进行性肾功能减退。
[2] Jongs, N., et al. (2021). Effect ofdapagliflozin on urinary albumin excretion in patients with chronic kidneydisease with and without type 2 diabetes: a prespecified analysis from theDAPA-CKD trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/S2213-8587(21)00243-6 ...
"We found that dapagliflozin delayed the initiation of dialysis and reduced the number of deaths," regardless of diabetes status, Heerspink, from the University Medical Centre Groningen, the Netherlands, said during a press conference. "The DAPA-CKD trial has shown dapagliflozin's potential as a ...
"We found that dapagliflozin delayed the initiation of dialysis and reduced the number of deaths," regardless of diabetes status, Heerspink, from the University Medical Centre Groningen, the Netherlands, said during a press conference. "The DAPA-CKD trial has shown dapagliflozin's potential as a ...
[2]. Heerspink HJL, Stefansson BV, Chertow GM,et al. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant (2020) 35: 274–282. ...
3.Ricardo Correa-Rotter, et al. Effects of Dapagliflozin in Patients with CKD and Albuminuria, with and Without Diabetes, by Use and Non-Use of Cardiovascular Medications: DAPA-CKD Trial [Abstract]. J Am Soc Nephrol 32, 2021: 725.
1. 58th ERA-EDTA Congress 2021-Abstract Supplement-FC063-Dapagliflozin decreases albuminuria in patients with chronic kidney disease with and without type 2 diabetes: Insights from the DAPA-CKD trial 2. 58th ERA-EDTA Congress 2021- Late Breaking ClinicalTrials-Presentation ID MO1060- Dapagliflozin ...